Genetic
MB-CART2019.1
MB-CART2019.1 is a genetic therapy with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
GENETIC
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_2
2
50%
Ph not_applicable
1
25%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting3
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 22 (50.0%)
N/A1 (25.0%)
Trials by Status
recruiting375%
not_yet_recruiting125%
Recent Activity
3 active trials
Showing 4 of 4
recruitingphase_2
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
NCT04844866
recruitingphase_2
DALY II Japan/MB-CART2019.1 for DLBCL
NCT07288879
recruitingnot_applicable
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
NCT06508775
not_yet_recruitingphase_1
MB-CART2019.1 in Refractory Multiple Sclerosis
NCT07178431
Clinical Trials (4)
Showing 4 of 4 trials
NCT04844866Phase 2
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
NCT07288879Phase 2
DALY II Japan/MB-CART2019.1 for DLBCL
NCT06508775Not Applicable
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
NCT07178431Phase 1
MB-CART2019.1 in Refractory Multiple Sclerosis
All 4 trials loaded
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 4